Amgen Inc.

214.91+1.27+0.59%Vol 1.04M1Y Perf -11.60%
Sep 23rd, 2021 13:39 DELAYED
BID214.86 ASK214.94
Open212.51 Previous Close213.64
Pre-Market213.70 After-Market-
 0.06 0.03%  - -
Target Price
252.39 
Analyst Rating
Moderate Buy 2.11
Potential %
17.42 
Finscreener Ranking
     42.62
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★     46.51
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★     53.17
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
★★+     41.04
Price Range Ratio 52W %
6.97 
Earnings Rating
Neutral
Market Cap122.04B 
Earnings Date
27th Oct 2021
Alpha0.00 Standard Deviation0.07
Beta0.67 

Today's Price Range

212.30215.09

52W Range

210.28276.69

5 Year PE Ratio Range

13.2078.10

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-1.71%
1 Month
-5.32%
3 Months
-10.50%
6 Months
-12.81%
1 Year
-11.60%
3 Years
4.16%
5 Years
22.22%
10 Years
318.49%

TickerPriceChg.Chg.%
AMGN214.911.27000.59
AAPL146.881.03000.71
GOOG2 843.2824.51000.87
MSFT300.181.60000.54
XOM57.011.80003.26
WFC48.050.97002.06
JNJ165.561.63000.99
FB346.843.63001.06
GE103.795.25005.33
JPM161.545.63003.61
Financial StrengthValueIndustryS&P 500US Markets
0.90
1.30
0.78
3.98
6.50
Leverage Ratio 6.60
ProfitabilityValueIndustryS&P 500US Markets
74.00
30.20
43.80
37.90
22.34
RevenueValueIndustryS&P 500US Markets
25.48B
44.88
2.75
2.19
DividendsValueIndustryS&P 500US Markets
3.27
7.04
8.69
11.78
Payout ratio54.00
Earnings HistoryEstimateReportedSurprise %
Q02 20214.134.386.05
Q01 20214.003.70-7.50
Q04 20203.363.8113.39
Q03 20203.754.3716.53
Q02 20203.814.2511.55
Q01 20203.704.1712.70
Q04 20193.443.645.81
Q03 20193.513.664.27
Earnings Per EndEstimateRevision %Trend
9/2021 QR4.21-0.47Negative
12/2021 QR3.97-4.34Negative
12/2021 FY16.410.37Positive
12/2022 FY18.021.12Positive
Next Report Date27th Oct 2021
Estimated EPS Next Report4.21
Estimates Count9
EPS Growth Next 5 Years %8.40
Volume Overview
Volume1.04M
Shares Outstanding567.85M
Shares Float566.43M
Trades Count21.75K
Dollar Volume701.96M
Avg. Volume2.60M
Avg. Weekly Volume2.91M
Avg. Monthly Volume2.59M
Avg. Quarterly Volume2.41M

Amgen Inc. (NASDAQ: AMGN) stock closed at 213.64 per share at the end of the most recent trading day (a -0.8% change compared to the prior day closing price) with a volume of 2.54M shares and market capitalization of 122.04B. Is a component of S&P 500, NASDAQ 100, Dow Jones 30, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 24300 people. Amgen Inc. CEO is Robert A. Bradway.

The one-year performance of Amgen Inc. stock is -11.6%, while year-to-date (YTD) performance is -7.08%. AMGN stock has a five-year performance of 22.22%. Its 52-week range is between 210.28 and 276.69, which gives AMGN stock a 52-week price range ratio of 6.97%

Amgen Inc. currently has a PE ratio of 22.00, a price-to-book (PB) ratio of 14.88, a price-to-sale (PS) ratio of 4.79, a price to cashflow ratio of 13.20, a PEG ratio of 2.32, a ROA of 8.95%, a ROC of 15.82% and a ROE of 58.95%. The company’s profit margin is 22.34%, its EBITDA margin is 43.80%, and its revenue ttm is $25.48 Billion , which makes it $44.88 revenue per share.

Of the last four earnings reports from Amgen Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $4.21 for the next earnings report. Amgen Inc.’s next earnings report date is 27th Oct 2021.

The consensus rating of Wall Street analysts for Amgen Inc. is Moderate Buy (2.11), with a target price of $252.39, which is +17.42% compared to the current price. The earnings rating for Amgen Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amgen Inc. has a dividend yield of 3.27% with a dividend per share of $7.04 and a payout ratio of 54.00%.

Amgen Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 7.03, ATR14 : 4.00, CCI20 : -105.30, Chaikin Money Flow : -0.07, MACD : -3.94, Money Flow Index : 37.96, ROC : -5.62, RSI : 34.55, STOCH (14,3) : 1.31, STOCH RSI : 0.06, UO : 42.22, Williams %R : -98.69), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amgen Inc. in the last 12-months were: David M. Reese (Option Excercise at a value of $125 787), Jonathan P. Graham (Sold 11 110 shares of value $2 627 625 ), Nancy A. Grygiel (Option Excercise at a value of $406 500), Nancy A. Grygiel (Sold 2 500 shares of value $631 272 ), Robert A. Bradway (Option Excercise at a value of $4 019 715), Robert Sanders Williams (Sold 750 shares of value $183 043 ), Ronald D. Sugar (Option Excercise at a value of $358 200), Ronald D. Sugar (Sold 5 000 shares of value $1 206 490 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (43.48 %)
11 (45.83 %)
11 (47.83 %)
Moderate Buy
2 (8.70 %)
2 (8.33 %)
1 (4.35 %)
Hold
10 (43.48 %)
10 (41.67 %)
10 (43.48 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (4.35 %)
1 (4.17 %)
1 (4.35 %)
Summary RatingModerate Buy
2.11
Moderate Buy
2.06
Moderate Buy
2.07

Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (approved 2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine). Amgen's own biosimilar portfolio includes key products Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

CEO: Robert A. Bradway

Telephone: +1 805 447-1000

Address: One Amgen Center Drive, Thousand Oaks 91320-1799, CA, US

Number of employees: 24 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

68%32%

Bearish Bullish

57%43%

Bearish Bullish

57%43%

TipRanks News for AMGN

Thu, 23 Sep 2021 08:35 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Thermo Fisher (TMO) and Surface Oncology (SURF)

- TipRanks. All rights reserved.

Mon, 20 Sep 2021 13:35 GMT Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Marinus (MRNS) and Spectrum Pharmaceuticals (SPPI)

- TipRanks. All rights reserved.

Fri, 17 Sep 2021 16:50 GMT Amgen (AMGN) Receives a Hold from William Blair

- TipRanks. All rights reserved.

Fri, 17 Sep 2021 16:47 GMT Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Actinium Pharmaceuticals (ATNM) and Axsome Therapeutics (AXSM)

- TipRanks. All rights reserved.

Thu, 19 Aug 2021 08:55 GMT Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Enanta Pharmaceuticals (ENTA) and Premier (PINC)

- TipRanks. All rights reserved.

Mon, 09 Aug 2021 01:51 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Karuna Therapeutics (KRTX) and Intellia Therapeutics (NTLA)

- TipRanks. All rights reserved.

Fri, 06 Aug 2021 09:35 GMT Heres What Amgens Newly Added Risk Factors Reveal

- TipRanks. All rights reserved.

Thu, 05 Aug 2021 07:15 GMT Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Owens & Minor (OMI) and Inspire Medical Systems (INSP)

- TipRanks. All rights reserved.

Wed, 04 Aug 2021 14:48 GMT Analysts Cautious of Amgen After Lukewarm Q2

- TipRanks. All rights reserved.

Wed, 04 Aug 2021 12:25 GMT Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS), Amgen (AMGN) and AstraZeneca (AZN)

- TipRanks. All rights reserved.

News

Stocktwits